Genentech, a member of Roche Holding AG, has recently commenced construction on a cutting-edge manufacturing facility in Holly Springs, North Carolina. This significant $700 million project is part of Roche's substantial $50 billion investment in U.S. manufacturing, infrastructure, and R&D. The facility will focus on producing next-generation metabolic medicines, including treatments for obesity, and is expected to generate over 1,900 jobs. The site, strategically located in a biopharmaceutical innovation hub, is designed for high-volume, efficient, and sustainable production and is set to be operational by 2029. This development underscores Roche's commitment to delivering life-changing treatments to patients more efficiently and expanding its U.S. presence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.